

PROFICIENCY TESTING PROGRAM 2021

Scheme Code D6402R1

Assay by UV-VIS Spectrophotometry

PROFICIENCY TESTING PROTOCOL

No. D6402R1

Organized by

Bureau of Drug and Narcotic Department of Medical Sciences 88/7 Soi Bumrasnaradura Hospital, Tiwanon Road, Nonthaburi, 11000 THAILAND Tel. +66 2951 0000 ext. 99137 Fax +66 2580 5733 Email: pt_bdn@hotmail.com; pts.bdn@gmail.com



1. ORGANIZER

Scheme Provider:

Bureau of Drug and Narcotic (BDN) Department of Medical Sciences 88/7 Soi Bumrasnaradura Hospital, Tiwanon Road, Nonthaburi, 11000, THAILAND Tel. +66 2951 0000 ext. 99137 Fax +66 2580 5733

Scheme Coordinator:

Ms. Siriphorn Laomanacharoen Pharmacist, Senior professional level Email: pt_bdn@hotmail.com; pts.bdn@gmail.com The scheme coordinator is responsible for all activities of the PT scheme.

2. OBJECTIVE

The objective of this Proficiency Testing (PT) scheme is to demonstrate that participants can accurately perform assay by UV-VIS Spectrophotometry. The scheme is based on the analysis of pharmaceutical product, cimetidine tablet, according to the method from the British Pharmacopoeia (BP) 2020 in Cimetidine Tablets monograph.

3. SUBCONTRACT

BDN has no policy to subcontract in any activity of this proficiency testing scheme.

4. CRITERIA FOR PARTICIPATION

Participants should have competences to perform assay of pharmaceutical product by UV-VIS spectrophotometry and use this technique in the routine work. Each participant is able to participate in the program for one set of PT sample.

5. NUMBER AND TYPE OF PARTICIPANTS

Number of participants:	20 – 80 laboratories
Type of participants:	Quality control laboratories in pharmaceutical manufacturers and other testing laboratories



Bureau of Drug and Narcotic Department of Medical Sciences

D6402R1: Assay by UV-VIS Spectrophotometry

6. SCHEDULE OF PT SCHEME

The frequency of this PT program is at least one round per 2 years. Schedule for the PT activities is as follows:

Activity	Schedule
Call for participation	December 2020
Deadline for registration	31 January 2021
Distribution of samples	February 2021
Deadline for submission of results	31 March 2021
Interim report for comments	May 2021
Final report	June 2021

For the best efficiency of PT program, all activities will be operated according to this time frame. Participants are requested to feedback for registration and submission of result according to the schedule. Participants should note that results submitted are not allowed to change or amend in any case.

5. **REGISTRATION**

Registration Fee:

Local participants5,000.- BahtOversea participants200.- USD (Including shipping handling)

Payment:

Local participants-

The payment should be made by Teller payment system at any branches of Krung Thai Bank Public Company Limited.

Overseas participants-

The payment should be made by bank transfer to

e pu	e payment should be made by bank transfer to		
	Account name:	DMSc Non-Fiscal Budget Account	
	Account number:	130-1034924	
	Bank name:	Krung Thai Bank Public Company Limited	
	Branch address:	88/20 1st Floor Block E Ministry of Public Health Moo	
		4 Soi Bamrat Naradul, Tiwanon Road, Talat Khwan,	
		Mueang Nonthaburi, Nonthaburi, 11000	
	Swift code:	KRTHTHBK	



Method and Deadline for Registration:

Participants should register online via the website https://www.bdn.go.th/pt within

<u>31 January 2021</u>. Registration by other means e.g. fax, Email will not be accepted.

Terms and Conditions:

- 1. BDN reserves the right to occasionally delay the issue of PT program or use an appropriate substitute test material with prior warning to participants if the planned PT sample is not available according to the schedule of PT scheme.
- 2. The registration fees are nonrefundable.

More information can be viewed on the website https://www.bdn.go.th/pt.

8. PROFICIENCY TESTING SAMPLE

The sample of this scheme is pharmaceutical product, cimetidine 200 mg tablet.

9. HANDLING OF PT SAMPLE

Participants will receive (i) 3×10 tablets of cimetidine 200 mg tablet, (ii) a bottle of cimetidine reference standard for PT containing about 120 mg and (iii) four pieces of Whatman GF/C filter.

PT samples are packed in blisters and should be stored below 30°C. Reference standard are packed in 4-ml amber glass bottle with plastic screw cap and should be stored between 2-8°C and protected from light and humidity until analysis. All of them are labeled which show the details of name, amount and storage condition and packed in vacuum plastic package. They are distributed in ambient condition.

PT samples are sent by express mail for local participants and by courier for oversea participants. It is the responsibility of the participants to contact BDN as soon as possible if they have not received the PT sample within the time schedule. In case of international transport for overseas participants, BDN cannot be responsible for any delays from the custom clearance. Upon receipt of PT sample, participants are requested to check physical conditions of PT sample as well as other substances provided and complete a PT sample acknowledgement form via the website https://www.bdn.go.th/pt.

10. TEST METHOD

Participants should determine in triplicates the percent labelled content of cimetidine $(C_{10}H_{16}N_6S)$ and report the results with **one digit after the decimal separator**. In case



number of digit reported is different from that specified in the protocol, the results will be rounded to one digit by BDN. If the right of the last decimal place is smaller than 5, it is eliminated and the preceding digit is unchanged. If the right of the last decimal place is equal to or greater than 5, it is eliminated and the preceding digit is increased by 1. Results reported with no digit after decimal separator or less than that specified in the protocol, 0 will be substituted. Range of percent labelled content for this PT sample is 95.0 - 105.0%.

Analysis is based on the assay method specified in Cimetidine Tablets monograph of BP 2020 and Appendix IIB Ultraviolet and visible absorption spectrophotometry according to the following procedure.

Procedure:

Weigh and finely powder 20 tablets. Shake a quantity of the powdered tablets containing 0.1 g of cimetidine with 300 mL of 0.05 M sulfuric acid for 20 minutes, add sufficient 0.05M sulfuric acid to produce 500 mL and filter (Whatman GF/C is suitable). Dilute 5 mL of the filtrate to 100 mL with 0.05M sulfuric acid (solution A). Prepare a 0.001% w/v solution of cimetidine reference standard in 0.05M sulfuric acid (solution B). Measure the absorbance of solutions A and B at the maximum at 218 nm and at 260 nm, Appendix II B. Calculate the content of $C_{10}H_{16}N_6S$ using the difference between the absorbances of solutions A and B at the two wavelengths and the declared content of $C_{10}H_{16}N_6S$ in cimetidine reference standard.

Details of the method are described in the testing protocol which can be downloaded via auto Email from website https://www.bdn.go.th/pt. PT sample as well as analytical procedure should be handled and operated in the same manner as performing routine work.

11. ASSIGNED VALUE

The assigned value used to calculate z score is based on the consensus value from participants using the robust mean calculated according to robust analysis: Algorithm A in Annex C of ISO 13528:2015 (E)-Statistical methods for use in proficiency testing by interlaboratory comparisons. The assigned value will not be disclosed to public until the report is issued.

The standard uncertainty of the assigned value x_{pt} is estimated as

$$u(x_{pt}) = 1.25 \times \frac{s^*}{\sqrt{p}}$$

Criteria: If

 $u(x_{pt}) < 0.3 \sigma_{pt}$



then, the uncertainty of the assigned value is negligible and need not to be included in the interpretation of the results.

12. STANDARD DEVIATION FOR PROFICIENCY ASSESSMENT

Standard deviation for proficiency assessment used to calculate z scores is set as 2.0% that corresponds to the level of performance and the expected precision of the test method or techniques and according to fitness for purpose.

13. PERFORMANCE EVALUATION

Participants will be assessed on the differences between their results and the assigned value. The z score is used for the performance evaluation as

$$Z_i = \frac{(x_i - x_{pt})}{\sigma_{pt}}$$

 $Z_i = z$ score

 x_i = measurement result from participant

 x_{pt} = assigned value

 σ_{pt} = standard deviation for proficiency assessment

The interpretation of z score is designated as follows.

$ z \leq 2.0$: acceptable
2.0 < z < 3.0	: warning signal
$ z \ge 3.0$: unacceptable

When $u(x_{pt}) > 0.3\sigma_{pt}$, then the uncertainty can be taken into account by expanding the denominator of the performance score and calculated as \dot{z} score

$$z'_i = \frac{x_i - x_{pt}}{\sqrt{\sigma_{pt}^2 + u^2(x_{pt})}}$$

The interpretation of z'score is as same as z score and using the same critical values of 2.0 and 3.0, depending on the design for the PT scheme.



Bureau of Drug and Narcotic Department of Medical Sciences

D6402R1: Assay by UV-VIS Spectrophotometry

For warning signal or unacceptable results, it is recommended that participants should investigate root causes and take necessary corrective actions.

14. POTENTIAL MAJOR SOURCES OF ERRORS

- 1. Suitability of analytical balance used and weighing procedure
- 2. Accuracy of sample and reference standard solution preparation
- 3. Suitability of UV-VIS spectrophotometer
- 4. Calculation
- 5. Moisture uptake due to inappropriate sample handling
- 6. Analytical wavelength maximum used

15. REPORT

An interim report is issued to provide each participant with an early indication of performance. In general, the interim report is issued about two months after the deadline for submission of results via the website https://www.bdn.go.th/pt. Participants are requested to check and review for any correction and/or comment. The final report is issued via the website https://www.bdn.go.th/pt after the correction and/or comment of interim report has been completed.

The report includes the following information.

- Introduction: general description of PT scheme
- Name and contact details of proficiency testing provider and scheme coordinator
- Participation: information of participating laboratories
- PT sample: description, sample preparation
- Homogeneity and stability assessment
- Assigned value, including measurement uncertainty and standard deviation of proficiency assessment
- Results: result tables including statistic summary data, z scores and bar chart of z scores
- Discussion of results: conclusion of overall performance and comments on participants' performance
- Potential major sources of errors

16. CONFIDENTIALITY, COLLUSION AND FALSIFICATION OF RESULTS

The identities of participants are protected by means of laboratory codes which are randomly assigned in each PT round. These codes are confidential and are not disclosed to other persons unless agreed by the participant for a regulatory or recognition purpose. Participants can access their personal information in the website https://www.bdn.go.th/pt by using username and password which can keep their information confidentially. For security purpose, participants are recommended to change username and password in case of changing the responsible person who can access the information in the website.



This PT scheme is conducted in the belief that participants will perform the analysis and report results with scientific professional. Where any collusion between participants or falsification of results is proven by BDN, the result of that participant for the PT round concerned will be cancelled for performance evaluation.

17. LOST OR DAMAGED OF PROFICIENCY TESTING SAMPLE

Auto Email will be sent to inform participants after sample distribution. In case of lost or damaged PT sample, participants should immediately inform BDN via https://www.bdn.go.th/pt. In some cases, the damaged PT sample should be returned to BDN. Replacement will be arranged within 1 week if the PT samples are proved to be lost or considered not suitable for analysis. The deadline of submitting result will be extended to appropriate date if necessary.